Global Hepatitis C Therapeutics Clinical Trials Market Review Research Reports

DALLAS, January 23, 2015 /PRNewswire/ --

LifeScienceIndustryResearch.com adds Hepatitis C Global Clinical Trials Review, H2, 2014 as well as Hepatitis C Market & Forecast, HCV Drugs Clinical Trials, Hepatitis C Pipeline Drugs Sales & Forecast - Worldwide research reports to its store.  

The report, "Hepatitis C Global Clinical Trials Review, H2, 2014" provides data on the Hepatitis C clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hepatitis C. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Hepatitis C. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis.

Scope 

Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each

Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type

Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy 

Understand the dynamics of a particular indication in a condensed manner

Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more

Obtain discontinued trial listing for trials across the globe

Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Comprehensive Table of Contents and more for the report "Hepatitis C Global Clinical Trials Review, H2, 2014" is available at http://www.lifescienceindustryresearch.com/hepatitis-c-global-clinical-trials-review-h2-2014.html . Order a copy of this report at http://www.lifescienceindustryresearch.com/purchase?rname=28368 .

Hepatitis C market by 2018 is expected to grow more than 3 times from its current market size of 2012. Hepatitis C virus (HCV) infection is a complex public health problem, characterized by a high prevalence of chronic infection, an increasing burden of HCV-associated disease, low rates of testing, treatment and the prospect of increasing incidence associated with the epidemic of injection drug use. Hepatitis C is a leading cause of chronic liver disease, end-stage cirrhosis and liver cancer. Because of the slow progression and asymptomatic character of the infection, many people are unaware of having it. As a consequence, the infection is often diagnosed at a late stage when treatment options are limited. As no effective vaccine against the Hepatitis C virus (HCV) has been discovered so far the market is driven by therapeutics. The increase in the prevalence of the disease and the availability of new first-in-class therapies with better safety and efficacy profiles are expected to drive the growth of the HCV market. The growth in HCV drugs market is primarily attributed to high unmet need in the market which is expected to be fulfilled by strong pipeline candidates. Low levels of awareness and knowledge about HCV have been identified as a formidable challenge to prevention and care.

This study titled "Hepatitis C Market & Forecast, HCV Drugs Clinical Trials, Hepatitis C Pipeline Drugs Sales & Forecast - Worldwide" provides a comprehensive assessment of the fast-evolving, high-growth of Hepatitis sector. This 164 page report with 25 Figures and 2 Tables studies the Hepatitis C Drug Market Landscape. This report contains 7 chapters.

Hepatitis C Drugs Market & Forecast (Chapter 2)

Hepatitis C Approved Drugs Sales & Forecast (Chapter 3)

Hepatitis C Deals & Acquisitions (Chapter 4)

Hepatitis C - Pipeline Drugs Clinical Trials (Drugs in Phase III) (Chapter 5)

Hepatitis C - Pipeline Drugs Clinical Trials (Drugs in Phase II) (Chapter 6)

Hepatitis C - Pipeline Drugs Sales Forecast (Chapter 7)

Hepatitis C - Approved Drugs sales & Forecast Analysis (To 2016) (Chapter No. 3)

Pegasys, Pegintron, Incivek & Victrelis

Data Sources 

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Renub Research team of industry experts.

Primary sources include industry surveys and telephone interviews with industry experts.

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Government Agencies, Magazines, Newspapers, Trade associations, Books, Industry Portals, Industry Associations and access to more than 500 paid databases.

Comprehensive Table of Contents and more for the report "Hepatitis C Market & Forecast, HCV Drugs Clinical Trials, Hepatitis C Pipeline Drugs Sales & Forecast - Worldwide" is available at http://www.lifescienceindustryresearch.com/hepatitis-c-market-forecast-hcv-drugs-clinical-trials-hepatitis-c-pipeline-drugs-sales-forecast-worldwide.html . Order a copy of this report at http://www.lifescienceindustryresearch.com/purchase?rname=14764 .  

Explore more reports on pharmaceuticals and the healthcare industry at http://www.lifescienceindustryresearch.com/category/healthcare .

About Us: 

Life Science Industry Research brings to you to the latest reports in market research on Biotechnology, Diagnostics, Healthcare, Medical Devices and Pharmaceuticals segments from leading research publishers across the globe. These reports also cover data and information on sub-segments and sectors under these life sciences categories.

Contact:  

Ritesh Tiwari

TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252

Tel:  +1-888-391-5441

sales@lifescienceindustryresearch.com